PixarBio (PixarBio) Treasury Stock : $0.00 Mil (As of Sep. 2016)

View and export this data going back to 2016. Start your Free Trial

What is PixarBio Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. PixarBio's treasury stock for the quarter that ended in Sep. 2016 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

PixarBio Treasury Stock Historical Data

The historical data trend for PixarBio's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Treasury Stock Chart

PixarBio Annual Data

Trend

Dec14

Dec15

Treasury Stock

PixarBio Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Treasury Stock	Get a 7-Day Free Trial					-	-	-	-	-

PixarBio Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

PixarBio (PixarBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155

Website

https://www.pixarbio.com

PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.